An Ad26‐MVA‐BN‐based therapeutic vaccine targeting HPV16 and HPV18 related disease is immunogenic in preclinical models and in women with persistent HPV infections.
Saved in:
| Title: | An Ad26‐MVA‐BN‐based therapeutic vaccine targeting HPV16 and HPV18 related disease is immunogenic in preclinical models and in women with persistent HPV infections. |
|---|---|
| Authors: | Khan, Selina1 (AUTHOR) selina.khan@oncodeaccelerator.nl, Boedhoe, Satish1 (AUTHOR), Baert, Miranda1 (AUTHOR), Serroyen, Jan1 (AUTHOR), Verbinnen, Thierry2 (AUTHOR), Volkmann, Ariane3 (AUTHOR), Kalla, Markus3 (AUTHOR), Weidner, Katrin3 (AUTHOR), Gars, Mathieu Le1 (AUTHOR), Sadoff, Jerry1 (AUTHOR), Sarnecki, Michal4 (AUTHOR), Vellinga, Jort1 (AUTHOR), Custers, Jerome1 (AUTHOR), Scheper, Gert1 (AUTHOR), Schuitemaker, Hanneke1 (AUTHOR), Zahn, Roland1 (AUTHOR) rzahn@its.jnj.com |
| Source: | Clinical & Translational Immunology. Mar2026, Vol. 15 Issue 3, p1-15. 15p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 20500068 |
|---|---|
| DOI: | 10.1002/cti2.70089 |
